...
首页> 外文期刊>The Journal of Urology >Endoscopic versus laparoscopic management of noninvasive upper tract urothelial carcinoma: 20-year single center experience
【24h】

Endoscopic versus laparoscopic management of noninvasive upper tract urothelial carcinoma: 20-year single center experience

机译:内镜与腹腔镜治疗无创上尿路尿路上皮癌:20年单中心经验

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose: We compare the outcomes of endoscopic surgery to laparoscopic nephroureterectomy for the management of specifically noninvasive upper tract urothelial carcinoma. Materials and Methods: A retrospective database review identified consecutive patients with clinically noninvasive upper tract urothelial carcinoma who underwent endoscopic surgery (59, via ureteroscopic ablation or percutaneous resection) or laparoscopic nephroureterectomy (70) at a single center during 20 years (1991 to 2011). Overall survival, upper tract urothelial carcinoma specific survival, upper tract recurrence-free survival, intravesical recurrence-free survival, progression-free survival and renal unit survival were estimated using Kaplan-Meier methods, with differences assessed using the log rank test. Results: Median age and followup were 74.8 years and 50 months, respectively. Overall renal preservation in the endoscopic group was high (5-year renal unit survival 82.5%), although this came at a cost of high local recurrence (endoscopic surgery 5-year recurrence-free survival 49.3%, laparoscopic nephroureterectomy 100%, p <0.0001). For G1 upper tract urothelial carcinoma, endoscopic surgery 5-year disease specific survival (100%) was equivalent to that of laparoscopic nephroureterectomy (100%). However, laparoscopic nephroureterectomy demonstrated superior disease specific survival to endoscopic surgery for G2 disease (91.7% vs 62.5%, p = 0.037) and superior progression-free survival for G3 disease (88.9% vs 55.6%, p = 0.033). Conclusions: For G1 upper tract urothelial carcinoma, endoscopic management can provide effective oncologic control and renal preservation. However, endoscopic management should not be considered for higher grade disease except in compelling imperative cases or in patients with poor life expectancy as oncologic outcomes are inferior to those of laparoscopic nephroureterectomy.
机译:目的:我们比较内镜手术与腹腔镜肾结直肠癌切除术治疗无创上尿路尿路上皮癌的疗效。资料和方法:回顾性数据库审查确定了连续20年(1991年至2011年)在同一中心接受内镜手术(59例,通过输尿管镜消融或经皮切除术)或腹腔镜肾结直肠癌切除术的临床无创性上尿路尿路上皮癌患者。 。使用Kaplan-Meier方法评估总体生存率,上尿路尿路上皮癌特异性生存率,无上尿复发率,无膀胱内复发率,无进展生存率和肾单位生存率,并采用对数秩检验评估差异。结果:中位年龄和随访时间分别为74.8岁和50个月。内镜组的总体肾脏保留率很高(5年肾单位生存率82.5%),尽管这样做的代价是局部复发率高(内镜手术5年无复发生存率49.3%,腹腔镜肾结石切除术100%,p < 0.0001)。对于G1上尿路上皮癌,内镜手术5年疾病特异性存活率(100%)与腹腔镜肾结直肠癌切除术(100%)相当。但是,对于G2疾病,腹腔镜肾切除术表现出比内镜手术优越的疾病特异性生存率(91.7%vs 62.5%,p = 0.037)和对于G3疾病而言无疾病进展的优越生存率(88.9%vs 55.6%,p = 0.033)。结论:对于G1上尿路尿路上皮癌,内镜处理可提供有效的肿瘤控制和肾脏保存。但是,除非是强制性病例或预期寿命较差的患者,否则不应考虑对高级别疾病进行内镜处理,因为其肿瘤学疗效不如腹腔镜肾结石切除术。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号